@article {44441,
	title = {cRGD functionalized nanocarriers for targeted delivery of bioactives},
	journal = {Journal of Drug Targeting},
	volume = {27},
	year = {2019},
	month = {FEB},
	pages = {111-124},
	type = {Article},
	abstract = {<p>The integrins αvβ3 play a very imperative role in angiogenesis and are overexpressed in endothelial cells of the tumor. Recent years have witnessed huge exploration in the field of αvβ3 integrin-mediated bioactive targeting for treatment of cancer. In these studies, the cRGD peptide has been employed extensively owing to their binding capacity to the αvβ3 integrin. Principally, RGD-based approaches comprise of antagonist molecules of the RGD sequence, drug-RGD conjugates, and most importantly tethering of the nanocarrier surface with the RGD peptide as targeting ligand. Targeting tumor vasculature or cells via cRGD conjugated nanocarriers have emerged as a promising technique for delivering chemotherapeutic drugs and imaging agents for cancer theranostics. In this review, primary emphasis has been given on the application of cRGD-anchored nanocarriers for targeted delivery of drugs, imaging agents, etc. for tumor therapy.</p>
},
	keywords = {alpha(v)beta(3) integrin receptors, cancer, cRGD, nanocarriers, targeting},
	issn = {1061-186X},
	doi = {10.1080/1061186X.2018.1473409},
	author = {Gajbhiye, Kavita Rai and Gajbhiye, Virendra and Siddiqui, Imtiaz A. and Gajbhiye, Jayant M.}
}
